UNICREDIT BANK/PUT/MODERNA/100/0.1/18.09.24 | Real-time BOERSE MUENCHEN 09:40:12 2024-06-21 am EDT | ||
| 0.25 EUR | +4.17% |
|
| Current month | +14.29% | ||
| 1 month | +4.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 0.25 | +4.17% |
| 24-06-20 | 0.24 | 0.00% |
| 24-06-19 | 0.24 | 0.00% |
| 24-06-18 | 0.24 | +20.00% |
| 24-06-17 | 0.2 | +5.26% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 09:40 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| WKN | HD03ZE |
| ISIN | DE000HD03ZE7 |
| Date issued | 2023-10-23 |
| Strike | 100 $ |
| Maturity | 2024-09-18 (89 Days) |
| Parity | 10 : 1 |
| Emission price | 2.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.3 € |
|---|---|
| Lowest since issue | 0.014 € |
| Spread | 0.03 € |
| Spread % | 12.50% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
134.4
USD
Average target price
145.2
USD
Spread / Average Target
+8.05%
- Stock Market
- Warrants
- Warrant
